Potential therapeutic drug candidates against SARS-CoV-2 (COVID‐19) through molecular docking: A review

The severe acute respiratory syndrome coronavirus 2 (known as COVID-19), initially appeared in the Wuhan city of China in December
2019, has become a current medical issue around the world. Due to its highly contagious nature, COVID-19 has spread widely to all
countries. As no effective treatment or vaccine is developed for this infectious disease, preventive measures are the only mandatory
strategy to stop its human-to-human transmission. In the present spread of COVID-19, the discovery of antiviral drugs is crucially
important as the development of these drugs often takes time. However, no specific drug has yet been approved for COVID-19. In this
review, we focus on the available drug candidates used for the treatment of infections caused by COVID-19 to identify potential
inhibitors through molecular docking